Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly EBT Margin of 1277.02% for Q1 2026, up 25623.0% year-over-year from N/an in Q1 2025, and down 218.51% quarter-over-quarter from 400.94% in Q4 2025.
Powered by 
Analysis
Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported EBT Margin for 12 consecutive years, with 1277.02% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 25623.0% year-over-year to 1277.02%; the TTM figure through Mar 2026 stood at 945.8% (up 51888.0% YoY), while the FY2025 annual figure was 1960.12%, up 23361.0% from the prior year.
- EBT Margin declined to 1277.02% in Q1 2026 per NTLA's latest filing, from 400.94% in the prior quarter.
- Across five years, EBT Margin topped out at 8521.39% in Q4 2023 and bottomed at 4122.35% in Q4 2022.
- Historically, EBT Margin has averaged 969.91% across 5 years, with a median of 1385.28% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 1447721 bps — and 2024, when it plunged 950139 bps.
- Intellia Therapeutics' EBT Margin stood at 4122.35% in 2022, then jumped by 307 bps to 8521.39% in 2023, then tumbled by 112 bps to 980.01% in 2024, then surged by 59 bps to 400.94% in 2025, then plunged by 219 bps to 1277.02% in 2026.
- Business Quant data shows NTLA's EBT Margin at 1277.02% in Q1 2026, 400.94% in Q4 2025, and 1613.8% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | -1,396.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,396.57% |
| Mar 31, 2026 | -633.49% |
| Dec 31, 2025 | -400.72% |
| Sep 30, 2025 | -760.14% |
| Jun 30, 2025 | -720.21% |
| Mar 31, 2025 | -674.83% |
| Dec 31, 2024 | -977.29% |
| Sep 30, 2024 | -1,455.91% |
| Jun 30, 2024 | -1,820.05% |
| Mar 31, 2024 | -350.34% |
| Dec 31, 2023 | 6,647.52% |
| Sep 30, 2023 | -987.05% |
| Jun 30, 2023 | -880.40% |
| Mar 31, 2023 | -793.10% |
| Dec 31, 2022 | -771.63% |
| Sep 30, 2022 | -780.83% |
| Jun 30, 2022 | -695.64% |
| Mar 31, 2022 | -1,277.16% |
| Dec 31, 2021 | -621.69% |
| Sep 30, 2021 | -994.50% |